RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication
- PMID: 10669333
- DOI: 10.1086/315270
RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication
Abstract
A prospective blinded study was conducted to determine whether immunological differences exist between patients receiving potent antiretroviral therapy who are able to achieve and maintain an undetectable virus load (<50 copies/mL) and those who are not. Eleven patients receiving protease inhibitor-containing antiretroviral therapy were studied for 1 year. After analysis of all baseline samples, patient virus load was disclosed, and patients were classified as suppressors (those who maintained undetectable virus load for 1 year) and nonsuppressors. Baseline virus load and CD4+ T cell count did not differ significantly between the 2 groups. Levels of RANTES production by CD4+ and CD8+ T cells and CD8-mediated inhibition of human immunodeficiency virus type 1 gene expression before initiation of antiretroviral therapy were significantly associated with an undetectable virus load maintained for 1 year (P<.05). Thus, a functionally intact T cell-mediated immune system at the time of initiation of potent antiretroviral therapy may predict long-term virus suppression.
Similar articles
-
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.J Infect Dis. 1999 Oct;180(4):1050-6. doi: 10.1086/315013. J Infect Dis. 1999. PMID: 10479130 Clinical Trial.
-
HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.Antivir Ther. 2007;12(6):971-5. Antivir Ther. 2007. PMID: 17926652
-
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Immunomodulatory effects of antiretroviral chemotherapy.J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):110-3. J Biol Regul Homeost Agents. 1995. PMID: 8782019 Review.
Cited by
-
Identifying methamphetamine use predictors in HIV infection: Immune-dopaminergic signatures in peripheral leukocytes and the role of COMT genotype.Brain Behav Immun Health. 2024 Oct 5;42:100873. doi: 10.1016/j.bbih.2024.100873. eCollection 2024 Dec. Brain Behav Immun Health. 2024. PMID: 39430881 Free PMC article.
-
Highly active antiretroviral therapy and beta-chemokines.Clin Exp Immunol. 2002 Nov;130(2):169-71. doi: 10.1046/j.1365-2249.2002.02010.x. Clin Exp Immunol. 2002. PMID: 12390302 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials